Nigrovic, Peter A.
Colbert, Robert A.
Holers, V. Michael
Ozen, Seza http://orcid.org/0000-0003-2883-7868
Ruperto, Nicolino http://orcid.org/0000-0001-8407-7782
Thompson, Susan D. http://orcid.org/0000-0003-4130-2796
Wedderburn, Lucy R. http://orcid.org/0000-0002-7495-1429
Yeung, Rae S. M. http://orcid.org/0000-0003-2361-725X
Martini, Alberto http://orcid.org/0000-0001-7642-1459
Article History
Accepted: 22 February 2021
First Online: 17 March 2021
Change Date: 29 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41584-021-00610-5
Competing interests
: P.A.N. declares support from investigator-initiated research grants from AbbVie, BMS, Novartis, Pfizer, and Sobi; consulting fees from BMS, Cerecor, Miach Orthopedics, Novartis, Pfizer, Quench Bio, Sigilon, Simcere, Sobi, and XBiotech; royalties from UpToDate Inc. and the American Academy of Pediatrics; and salary support from the Childhood Arthritis and Rheumatology Research Alliance. V.M.H. declares acting as a current or recent consultant to BMS, Celgene, Janssen R&D, and Q32 Bio, and support from research grants from Janssen R&D and Q32 Bio. S.O. declares receipt of consultancy or speaker fees from Novartis and Sobi. N.R. declares receipt of honoraria for consultancies or speaker bureaus in the past 3 years from Ablynx, AstraZeneca/MedImmune, Biogen, BMS, Boehringer Ingelheim, Eli Lilly, EMD Serono, F. Hoffmann-La Roche, GSK, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, R-Pharm, Sanofi, Servier, Sinergie, and Sobi. The IRCCS Istituto Giannina Gaslini, where N.R. works as a full-time public employee, has received contributions in the past 3 years from BMS, Eli Lilly, F. Hoffmann-La Roche, GSK, Janssen, Novartis, Pfizer, and Sobi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment with third parties. L.R.W. declares support from AbbVie, GSK, Pfizer, Sobi, and UCB to the CLUSTER Consortium. R.S.M.Y. declares one-time consulting fees from Eli-Lilly and Novartis. A.M. declares receipt of honoraria for consultancies from Aurinia, BMS, Eli-Lilly, EMD Serono, Janssen, and Pfizer. All other authors declare no competing interests.